Randomized Trial Highlights Uncertainties of Ambroxol to Improve Cognition in Parkinson Disease Dementia

A recent study confirmed ambroxol’s safety in Parkinson disease dementia, showing stabilization of neuropsychiatric symptoms but no cognitive improvement.:

Source: Neurology Read More

Previous PostMyasthenia Gravis Medication Nipocalimab Outperforms FcRn Blockers in Indirect Comparison Analysis
Next PostLivaNova’s VNS Therapy Maintains Effectiveness in Drug-Resistant Epilepsy in Latest 2-Year Data

Randomized Trial Highlights Uncertainties of Ambroxol to Improve Cognition in Parkinson Disease Dementia

Previous PostMyasthenia Gravis Medication Nipocalimab Outperforms FcRn Blockers in Indirect Comparison Analysis

Next PostLivaNova’s VNS Therapy Maintains Effectiveness in Drug-Resistant Epilepsy in Latest 2-Year Data

Related Posts

<![CDATA[Phase 3 Post Hoc Analysis Shows Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in Advanced Parkinson Disease ]]>

<![CDATA[DMD Management: Evolving Regimens and Real-World Adherence]]>

<![CDATA[NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus]]>

Categories